PTC Therapeutics | PTCT

Peers Price Chg Day Year Date
4568 Daiichi Sankyo 5,003.00 239.00 5.02% 6.22% Apr/26
ACAD Acadia Pharmaceuticals 16.32 -0.27 -1.63% -19.65% Apr/25
ALNY Alnylam Pharmaceuticals 143.70 -0.09 -0.06% -27.25% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMRN BioMarin Pharmaceutical 82.17 -9.07 -9.94% -11.65% Apr/25
CYTK Cytokinetics 64.84 -1.98 -2.96% 74.58% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
INCY Incyte 51.16 -0.62 -1.20% -30.43% Apr/25
IONS Ionis Pharmaceuticals 41.81 -0.65 -1.53% 16.95% Apr/25
IRWD Ironwood Pharmaceuticals 8.09 -0.01 -0.12% -22.36% Apr/25
NOVN Novartis 89.35 -0.65 -0.72% -2.19% Apr/26
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PTCT PTC Therapeutics 25.49 0.28 1.11% -51.21% Apr/25
RARE Ultragenyx Pharmaceutical 43.85 -0.41 -0.93% 3.59% Apr/25
ROG Roche Holding 219.30 0.50 0.23% -20.60% Apr/26
SRPT Sarepta Therapeutics 127.41 3.16 2.54% 4.20% Apr/25
TGTX TG Therapeutics 13.91 -0.07 -0.50% -37.06% Apr/25
VRTX Vertex Pharmaceuticals 397.24 -3.35 -0.84% 22.87% Apr/25
XNCR Xencor 19.23 0.21 1.10% -28.51% Apr/25

Indexes Price Day Year Date
CCMP USND 15612 -100.99 -0.64% 31.70% Apr/25
RTY US2000 1981 -14.31 -0.72% 13.13% Apr/26

PTC Therapeutics traded at $25.49 this Thursday April 25th, increasing $0.28 or 1.11 percent since the previous trading session. Looking back, over the last four weeks, PTC Therapeutics gained 8.83 percent. Over the last 12 months, its price fell by 51.21 percent. Looking ahead, we forecast PTC Therapeutics to be priced at 28.53 by the end of this quarter and at 26.93 in one year, according to Trading Economics global macro models projections and analysts expectations.

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).